The second quarter showed stable operational progress for Nuevolution and the company also completed a directed share issue as well as an up-listing to the Nasdaq Stockholm main market, improving the company's foundation. A potential high-value project was unveiled as the target of the "Cytokine X" was disclosed. We include the project in our valuation with this report, which together with some minor changes has a net positive effect, raising our valuation range.